KPV was studied in cultured cells and mouse models of colitis. There are limited human data on BPC-157, including a small colitis trial reported in a meeting abstract. These studies cannot establish which peptide works better or whether either is safe for this use.

Correction, November 16, 2026. The earlier version said neither peptide had completed human trials and that no human safety data existed. This update describes the FDA summary of a BPC-157 colitis trial and the limited observations from an intravenous pilot.

What the KPV experiments measured

Researchers exposed cultured human intestinal epithelial cells and T cells to KPV and found that uptake through the PepT1 transporter reduced inflammatory signaling. They also added KPV to the drinking water of mice in two models of induced colitis and reported reduced inflammation. A result in cultured human cells or mice cannot establish symptom relief in people. [1]

The FDA assessment did not identify human clinical studies or information sufficient to assess KPV safety in people. The mouse experiments cannot tell us how an oral KPV product would behave in humans.

What the BPC-157 studies in people reported

The FDA advisory committee material summarizes a 2005 meeting abstract describing a randomized, double-blind trial of rectal BPC-157 versus placebo in 53 participants with mild to moderate ulcerative colitis. The treatment period was two weeks. The FDA noted limited methods reporting and a confidence interval that included no between-group difference. The available findings do not establish a benefit.

An uncontrolled 2025 pilot administered BPC-157 intravenously to two adults who had received it previously. Over three days, the authors reported no measurable changes in the tested biomarkers and no reported adverse effects. The tiny sample and short follow-up leave safety uncertain, including for other routes. The pilot did not test whether BPC-157 helps colitis or heals injuries. [2]

What the registered hamstring trial could answer

The ClinicalTrials.gov record describes a randomized phase 2 trial for acute grade II hamstring strains. It plans to compare subcutaneous BPC-157 with placebo, with rehabilitation in both groups. The planned outcomes include time to return to unrestricted sport and MRI lesion volume. The registry had no posted results as of November 16, 2026. It concerns hamstring recovery and includes no KPV group.

There is no head-to-head comparison in these sources. The KPV and BPC-157 reports used different populations, routes and outcomes. Available evidence cannot tell readers which would work better for gut symptoms or whether either is safe for that use.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.

References

  1. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.. Gastroenterology, 2008.
  2. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.. Alternative Therapies in Health and Medicine, 2025.